142 related articles for article (PubMed ID: 26529923)
1. [Pharmacology of bone resorption inhibitor].
Menuki K; Sakai A
Nihon Rinsho; 2015 Oct; 73(10):1634-8. PubMed ID: 26529923
[TBL] [Abstract][Full Text] [Related]
2. Anti-resorptive therapies for osteoporosis.
Reid IR
Semin Cell Dev Biol; 2008 Oct; 19(5):473-8. PubMed ID: 18760372
[TBL] [Abstract][Full Text] [Related]
3. [[Antiresorptive agents in the treatment of osteoporosis].
Novak S
Reumatizam; 2014; 61(2):89-94. PubMed ID: 25427401
[TBL] [Abstract][Full Text] [Related]
4. [Current topics in drug therapy aiming at bone resorption].
Yasui T; Tanaka S
Clin Calcium; 2006 Sep; 16(9):1475-79. PubMed ID: 16951471
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and treatment of postmenopausal osteoporosis].
Mizunuma H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():490-4. PubMed ID: 18161154
[No Abstract] [Full Text] [Related]
7. Pharmacological diversity among drugs that inhibit bone resorption.
Russell RG
Curr Opin Pharmacol; 2015 Jun; 22():115-30. PubMed ID: 26048735
[TBL] [Abstract][Full Text] [Related]
8. [Molecular mechanisms of action of bisphosphonates and strontium ranelate].
Vengerovskiĭ AI; Khlusov IA; Nechaev KA
Eksp Klin Farmakol; 2014; 77(9):43-6. PubMed ID: 25365870
[TBL] [Abstract][Full Text] [Related]
9. Odanacatib for the treatment of osteoporosis.
Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
Väänänen K
Adv Drug Deliv Rev; 2005 May; 57(7):959-71. PubMed ID: 15876398
[TBL] [Abstract][Full Text] [Related]
11. Current and emerging therapies for osteoporosis.
Mitchner NA; Harris ST
J Fam Pract; 2009 Jul; 58(7 Suppl Osteoporosis):S45-9. PubMed ID: 19825319
[TBL] [Abstract][Full Text] [Related]
12. [Clinical implications of bisphosphonate for bone metastases of prostate cancer].
Kitagawa Y; Konaka H; Mizokami A; Namiki M
Nihon Rinsho; 2007 Nov; 65 Suppl 9():356-9. PubMed ID: 18161131
[No Abstract] [Full Text] [Related]
13. [Mechanisms of action of anticatabolic drugs used in osteoporosis therapy].
Kryśkiewicz E; Lorenc RS
Endokrynol Pol; 2009; 60(2):134-44. PubMed ID: 19396757
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Miki T; Minamide T
Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis and treatment of immobilization osteoporosis].
Inoue D
Nihon Rinsho; 2007 Nov; 65 Suppl 9():514-9. PubMed ID: 18159714
[No Abstract] [Full Text] [Related]
16. [Drug selection guide for osteoporosis determined by the clinical staging, pathophysiology and age].
Tanaka I; Oshima H
Nihon Rinsho; 2009 May; 67(5):915-20. PubMed ID: 19432109
[TBL] [Abstract][Full Text] [Related]
17. Bone markers and osteoporosis therapy.
Bandeira F; Costa AG; Soares Filho MA; Pimentel L; Lima L; Bilezikian JP
Arq Bras Endocrinol Metabol; 2014 Jul; 58(5):504-13. PubMed ID: 25166041
[TBL] [Abstract][Full Text] [Related]
18. Future developments in osteoporosis therapy.
Ng KW
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):371-84. PubMed ID: 19857200
[TBL] [Abstract][Full Text] [Related]
19. [Bone remodeling: new therapeutic approaches].
Ferrari S
Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
[TBL] [Abstract][Full Text] [Related]
20. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
